Literature DB >> 25685042

An example of using a decision making framework designed for non-medical prescribers as a method for enhancing prescribing safety for inhaled corticosteroids (ICS).

Saja Almarshad1.   

Abstract

Non-medical prescribing is needed especially with the increased demand for health care and the physicians' time constrains. Also, it is not well regulated in Saudi Arabia unlike the United Kingdom. This report aims to demonstrate the urged need for regulations to maintain a safe non-medical prescribing process. It also adapts the single competency framework provided by the United Kingdom national prescribing centre (NPC, 2012) to be utilised by the respiratory therapist for a safe prescribing process for inhaled corticosteroids (ICS) to control adult asthma as an example. The framework is thought to be an effective tool for safe non-medical prescribing and it is highly recommended to develop a national Saudi framework to maintain the patients' safety and utilise resources.

Entities:  

Keywords:  Asthma; Framework; Inhaled corticosteroids; Non-medical prescribing

Year:  2014        PMID: 25685042      PMCID: PMC4311001          DOI: 10.1016/j.jsps.2014.06.002

Source DB:  PubMed          Journal:  Saudi Pharm J        ISSN: 1319-0164            Impact factor:   4.330


  27 in total

1.  Prescribing behaviour in clinical practice: patients' expectations and doctors' perceptions of patients' expectations--a questionnaire study.

Authors:  J Cockburn; S Pit
Journal:  BMJ       Date:  1997-08-30

2.  A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial.

Authors:  L A Laitinen; A Laitinen; T Haahtela
Journal:  J Allergy Clin Immunol       Date:  1992-07       Impact factor: 10.793

Review 3.  Regulatory crosstalk at composite response elements.

Authors:  J N Miner; K R Yamamoto
Journal:  Trends Biochem Sci       Date:  1991-11       Impact factor: 13.807

Review 4.  The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysis.

Authors:  Chun E Jia; Hong Ping Zhang; Yan Lv; Rui Liang; Yun Qiu Jiang; Heather Powell; Juan Juan Fu; Lei Wang; Peter Gerard Gibson; Gang Wang
Journal:  J Allergy Clin Immunol       Date:  2012-10-08       Impact factor: 10.793

5.  Evaluation of two different educational interventions for adult patients consulting with an acute asthma exacerbation.

Authors:  J Côté; D M Bowie; P Robichaud; J G Parent; L Battisti; L P Boulet
Journal:  Am J Respir Crit Care Med       Date:  2001-05       Impact factor: 21.405

6.  Influence on asthma morbidity of asthma education programs based on self-management plans following treatment optimization.

Authors:  J Coté; A Cartier; P Robichaud; H Boutin; J L Malo; M Rouleau; A Fillion; M Lavallée; M Krusky; L P Boulet
Journal:  Am J Respir Crit Care Med       Date:  1997-05       Impact factor: 21.405

7.  Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma.

Authors:  A S Vathenen; A J Knox; A Wisniewski; A E Tattersfield
Journal:  Am Rev Respir Dis       Date:  1991-06

8.  Increased prevalence of asthma in Saudi Arabia.

Authors:  A R Al Frayh; Z Shakoor; M O Gad El Rab; S M Hasnain
Journal:  Ann Allergy Asthma Immunol       Date:  2001-03       Impact factor: 6.347

9.  Fluticasone/formoterol dry powder versus budesonide/formoterol in adults and adolescents with uncontrolled or partly controlled asthma.

Authors:  A Cukier; C M A Jacob; N A Rosario Filho; J Fiterman; E O Vianna; J L Hetzel; M A Neis; E Fiss; F F M Castro; A L G Fernandes; R Stirbulov; E Pizzichini
Journal:  Respir Med       Date:  2013-07-09       Impact factor: 3.415

10.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Authors:  Ian D Pavord; Stephanie Korn; Peter Howarth; Eugene R Bleecker; Roland Buhl; Oliver N Keene; Hector Ortega; Pascal Chanez
Journal:  Lancet       Date:  2012-08-18       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.